Pfizer Inc. (PFE) News
Filter PFE News Items
PFE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PFE News Highlights
- PFE's 30 day story count now stands at 26.
- Over the past 25 days, the trend for PFE's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
- The most mentioned tickers in articles about PFE are DRUG, AMP and TALK.
Latest PFE News From Around the Web
Below are the latest news stories about PFIZER INC that investors may wish to consider to help them evaluate PFE as an investment opportunity.
3 Stocks to Buy in October That Could Soar More Than 40% Over the Next 12 Months, According to Wall StreetBioNTech (NASDAQ: BNTX) has turned in a dismal performance so far this year. The average analysts' price target reflects an upside potential of 56%. Granted, not every analyst is all that bullish about BioNTech. |
Could Viatris Stock Help You Become a Millionaire?Viatris' broad portfolio gives the business lots of stability and plenty of opportunities -- but is there enough there for the stock to be a great long-term investment? |
Moderna's Shares Could Take Off if These 2 Things HappenModerna (NASDAQ: MRNA) used to be a stock market star, climbing 1,700% from the start of 2020 through July of 2021. Investors liked that, and it clearly showed in the stock performance. After all, the vaccine is Moderna's only product right now, and demand for it has declined. |
Unveiling Pfizer (PFE)'s Value: Is It Really Priced Right? A Comprehensive GuideA deep dive into Pfizer's current market valuation, financial strength, and growth prospects |
Why Pfizer and BioNTech Stocks Zoomed Higher TodayThe fight against COVID-19 isn't over yet, and the two companies remain very much in the battle. |
Structure Stock Soars. Its Obesity Pill Could Challenge Lilly, Novo.Analysts say that the arrival of cheaper, more convenient obesity pills could mean much broader access for patients, and eventually a larger market. |
Upstart Weight-Loss Drugmaker Jumps 75% on Strong Test Results(Bloomberg) -- Structure Therapeutics Inc. jumped to a record high Friday after new data on its oral weight-loss drug fueled expectations that the San Francisco-based company is closing the gap with larger competitors such as Pfizer Inc.Most Read from BloombergEurope’s Richest Royal Family Builds $300 Billion Finance EmpirePakistan Rupee Set to Become Top Performing Currency Globally Top Chinese Scientist Claims India Moon Landing Nowhere Near South PoleStock Optimism Fizzles as Quarterly Losses |
3 Stocks to Focus on as Demand for Obesity Drugs BoomsWith the obesity market gaining popularity, analysts are expecting sales to increase. Pharma companies are rushing to enter the market |
Where Will Pfizer Be in 5 Years?Investors should expect to see big changes from the company as it addresses concerns about its growth prospects. |
Bud Light boycott movement goes after Taylor Swift and Travis KelceThe Kansas City Chiefs tight end has become a popular spokesperson who has endorsed both Bud Light and Pfizer. |